Author:
Fueger Barbara J.,Yeom Kristen,Czernin Johannes,Sayre James W.,Phelps Michael E.,Allen-Auerbach Martin S.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology
Reference35 articles.
1. Hoh CK, Glaspy J, Rosen P et al (1997) Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 38(3):343–348
2. Jerusalem G, Beguin Y, Fasotte M et al (1999) Whole body positron emission tomograpohy using 18 F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433
3. Römer W, Hanauske A, Ziegler S et al (1998) Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464–4471
4. Buchmann I, Reinhardt M, Elsner K et al (2001) 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91(5):889–899
5. Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E (2005) Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin’s and non-Hodgkin’s lymphoma patients: when do we really need FDG-PET? Ann Oncol 16(9):1524–1529
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献